H.C. Wainwright Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $64
Rhythm Pharmaceuticals Price Target Announced at $64.00/Share by JMP Securities
Rhythm Pharmaceuticals Analyst Ratings
JMP Securities Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $64
Wells Fargo Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)
Morgan Stanley Sticks to Their Buy Rating for Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals Analyst Ratings
Needham Reiterates Buy on Rhythm Pharmaceuticals, Maintains $55 Price Target
Buy Rating Reaffirmed for Rhythm Pharmaceuticals Amid Strong Imcivree Sales and Promising Clinical Trials
Stifel Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $64
Stifel Nicolaus Reaffirms Their Buy Rating on Rhythm Pharmaceuticals (RYTM)
Needham Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $55
Needham Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $55
Rhythm Pharmaceuticals Analyst Ratings
CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $79
Buy Rating Affirmed for Rhythm Pharmaceuticals on Strong Drug Pipeline and Market Potential
Morgan Stanley Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals Analyst Ratings
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $79
Maintaining Buy Rating on Rhythm Pharmaceuticals: Positive Outlook Amidst Growth and Upcoming Catalysts